Photo of Mark Lewis from thepreventivemedicinepodcast.com
Sep 24, 2023, 22:29
Mark Lewis: After KEYNOTE-177 every patient with metastatic colon cancer should have MMR testing at the very least to assess their candidacy for immunotherapy.
Mark Lewis, Director and GI Oncology at Intermountain Healthcare, shared a post by The Oncologist, adding the following:
“After KEYNOTE-177 every patient with metastatic colon cancer should have MMR testing at the very least to assess their candidacy for immunotherapy. We almost never treat breast cancer without knowing receptor status and other solid tumors merit biomarker-informed care too!”
Quoting The Oncologist’s post:
“According to the results of this web-based survey, oncologists from rural areas and urban clusters were familiar with biomarker testing in mCRC. However, reported biomarker testing is still suboptimal based on guideline recommendations.”
For details click here
Source: Mark Lewis/Twitter and The Oncologist/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19